MCID: XLN206
MIFTS: 32

X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

MalaCards integrated aliases for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

Name: X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome 58
Johnson Syndrome 58

Characteristics:

Orphanet epidemiological data:

58
x-linked intellectual disability-macrocephaly-macroorchidism syndrome
Inheritance: X-linked recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 33 Q87.8
Orphanet 58 ORPHA85320
SNOMED-CT via HPO 68 61152003

Summaries for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

MalaCards based summary : X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome, also known as johnson syndrome, is related to dubin-johnson syndrome and stevens-johnson syndrome/toxic epidermal necrolysis. The drugs Gabapentin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and liver, and related phenotypes are macrocephaly and macroorchidism

Related Diseases for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Diseases related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 429)
# Related Disease Score Top Affiliating Genes
1 dubin-johnson syndrome 12.9
2 stevens-johnson syndrome/toxic epidermal necrolysis 12.8
3 severe cutaneous adverse reaction 12.5
4 stevens-johnson syndrome/toxic epidermal necrolysis overlap syndrome 12.4
5 erythema multiforme 12.2
6 erythema multiforme major 11.9
7 hyperbilirubinemia, rotor type 11.6
8 bilirubin metabolic disorder 11.6
9 gilbert syndrome 11.5
10 5-oxoprolinase deficiency 11.2
11 crigler-najjar syndrome, type ii 11.2
12 auditory neuropathy spectrum disorder 11.2
13 exanthem 10.7
14 conjunctivitis 10.5
15 mucositis 10.4
16 allergic hypersensitivity disease 10.4
17 cholestasis 10.4
18 yemenite deaf-blind hypopigmentation syndrome 10.4
19 lupus erythematosus 10.4
20 systemic lupus erythematosus 10.4
21 bronchiolitis 10.4
22 bronchiolitis obliterans 10.3
23 hypereosinophilic syndrome 10.3
24 keratitis, hereditary 10.3
25 skin disease 10.3
26 bullous pemphigoid 10.3
27 herpes simplex 10.3
28 stomatitis 10.3
29 respiratory failure 10.3
30 dermatitis 10.3
31 pneumonia 10.3
32 acute generalized exanthematous pustulosis 10.2
33 neutropenia 10.2
34 entropion 10.2
35 dysphagia 10.2
36 limbal stem cell deficiency 10.2
37 ocular cicatricial pemphigoid 10.2
38 acute kidney failure 10.2
39 liver disease 10.2
40 drug reaction with eosinophilia and systemic symptoms 10.2
41 autoimmune disease 10.2
42 autosomal recessive disease 10.2
43 corneal neovascularization 10.2
44 lung disease 10.2
45 cicatricial pemphigoid 10.1
46 purpura 10.1
47 endophthalmitis 10.1
48 cataract 10.1
49 fixed drug eruption 10.1
50 immune deficiency disease 10.1

Graphical network of the top 20 diseases related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:



Diseases related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome

Symptoms & Phenotypes for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Human phenotypes related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

58 31
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 macrocephaly 58 31 hallmark (90%) Very frequent (99-80%) HP:0000256
2 macroorchidism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000053
3 intellectual disability, moderate 58 31 hallmark (90%) Very frequent (99-80%) HP:0002342

Drugs & Therapeutics for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Drugs for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Azithromycin Approved Phase 4 83905-01-5 55185 447043
3
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
4
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
5
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
6
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8 Ophthalmic Solutions Phase 4
9 Anti-Bacterial Agents Phase 4
10 Antimetabolites Phase 4
11 Analgesics Phase 4
12 Central Nervous System Depressants Phase 4
13 Analgesics, Opioid Phase 4
14 Anti-Anxiety Agents Phase 4
15 Tranquilizing Agents Phase 4
16 Psychotropic Drugs Phase 4
17 Antimanic Agents Phase 4
18 Excitatory Amino Acid Antagonists Phase 4
19 Anticonvulsants Phase 4
20 Excitatory Amino Acids Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Hypolipidemic Agents Phase 4
23 Lipid Regulating Agents Phase 4
24 Neurotransmitter Agents Phase 4
25 Autonomic Agents Phase 4
26 Adrenergic Antagonists Phase 4
27 Adrenergic beta-Antagonists Phase 4
28 Sympatholytics Phase 4
29 Adrenergic Agents Phase 4
30 Sodium Channel Blockers Phase 4
31 Diuretics, Potassium Sparing Phase 4
32 Anti-Arrhythmia Agents Phase 4
33
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
34
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
35
Lesinurad Approved, Investigational Phase 3 878672-00-5 53465279
36
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
37
Etravirine Approved Phase 3 269055-15-4 193962
38
tannic acid Approved Phase 2, Phase 3 1401-55-4
39
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
40
Maraviroc Approved, Investigational Phase 2, Phase 3 376348-65-1 3002977
41
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
42
Etanercept Approved, Investigational Phase 3 185243-69-0
43
Coal tar Approved Phase 3 8007-45-2
44
Lamotrigine Approved, Investigational Phase 2, Phase 3 84057-84-1 3878
45
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
46 Hypoglycemic Agents Phase 3
47 Antirheumatic Agents Phase 3
48 Renal Agents Phase 3
49 Cytochrome P-450 Enzyme Inhibitors Phase 3
50 Cytochrome P-450 CYP3A Inducers Phase 3

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
3 Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction Completed NCT01977937 Phase 4 Gabapentin 250mg/5mL NDC:59762-5025-01;Simple Syrup
4 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
5 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
6 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
7 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
8 Transdermal Lidocaine Patch for Post-Cesarean Pain Control for Women With Obesity: a Single-blind Randomized Controlled Trial Active, not recruiting NCT03810235 Phase 4 Transdermal Lidocaine Patch;Transdermal Hydrocolloid Placebo Patch
9 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
10 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
11 Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction Completed NCT01237600 Phase 2, Phase 3
12 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
13 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor Completed NCT01508702 Phase 3 lesinurad;Placebo
14 A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125. Completed NCT00792324 Phase 3 Etravirine;Efavirenz
15 Maraviroc to Augment Rehabilitation Outcomes After Stroke Recruiting NCT03172026 Phase 2, Phase 3 Maraviroc 300 mg;Placebo 300 mg
16 NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 cyclosporin A;Etanercept 50 MG Solution for Injection;Placebos
17 Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study Terminated NCT00295776 Phase 2, Phase 3 Lamictal in the treatment of Post-Herpetic Neuralgia
18 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
19 Evaluation the Effect of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Epithelium Healing (Phase I and II Clinical Trial) Completed NCT02746848 Phase 1, Phase 2
20 Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-Centre Randomized Double Blind Controlled Trial in Pakistan Completed NCT00130013 Phase 1, Phase 2 Oral Amoxicillin
21 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
22 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
23 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
24 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
25 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
26 Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of Ocular Surface Reconstruction Completed NCT00344201 Phase 1
27 Topical Infliximab for the Treatment of Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
28 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Not yet recruiting NCT03878771 Phase 1 Dermovate cream in Orabase
29 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
30 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
31 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity. Unknown status NCT03166241
32 Drug Patch Tests, Enzyme-linked Immunosorbent Spot Assay (Elispot) and Lymphocyte Transformation Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs) Unknown status NCT03176342
33 The Use of Pentacam in Assessment of Corneal Changes After Pterygium Excision Unknown status NCT03304366
34 The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation Unknown status NCT00696982 sitagliptin;glibenclamide
35 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
36 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
37 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR) Completed NCT01276314 anti- TNF-a;Prednisolone
38 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
39 Urinary Ratio of the Coproporphyrins Isomers I and III and Its Relationships With Methotrexate Elimination in Patients With a Lymphoid Malignancy Completed NCT00822432
40 Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases Completed NCT00357071
41 Randomised Research Comparing Acupuncture, Herbal Treatment and Artificial Tear Eye Drops in Dry Eye Completed NCT02219204
42 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Recruiting NCT02574988
43 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
44 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
45 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Recruiting NCT02795143 Isotretinoin
46 The Effects of Autologous Simple Limbal Epithelial Transplantation. Recruiting NCT04021875
47 Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study Recruiting NCT01611636
48 The Effects of Allogeneic Simple Limbal Epithelial Transplantation Recruiting NCT04021134
49 An Exploratory Case-Control Study of Genetic and Clinical Factors for Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
50 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study Recruiting NCT03184597

Search NIH Clinical Center for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome

Genetic Tests for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Anatomical Context for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

MalaCards organs/tissues related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

40
Skin, Eye, Liver, Testes, T Cells, Lung, Heart

Publications for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Articles related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

(show top 50) (show all 3965)
# Title Authors PMID Year
1
Altered levels of complement components associated with non-immediate drug hypersensitivity reactions. 61
31795786 2020
2
Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. 61
31870573 2020
3
Long-term Progression of Ocular Surface Disease in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
32028281 2020
4
Long-term and multiple hospital readmissions after discharge for Stevens-Johnson Syndrome and toxic epidermal necrolysis. 61
32017033 2020
5
A retrospective analysis of infections and antibiotic treatment in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
30095319 2020
6
Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. 61
30702955 2020
7
Searching for the Culprit Drugs for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis from a Nationwide Claim Database in Korea. 61
31614216 2020
8
Predictors of 30-day readmission in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cross-sectional database study. 61
31542405 2020
9
Stevens-Johnson syndrome and toxic epidermal necrolysis - retrospective review of cases in a high complexity hospital in Brazil. 61
31173347 2020
10
Management of immune checkpoint inhibitor-related dermatologic adverse events. 61
31814310 2020
11
The Clinical and Financial Impact of a Pharmacist-Driven Penicillin Skin Testing Program on Antimicrobial Stewardship Practices. 61
31983768 2020
12
Pattern-Specific Loss of Desmoplakin I and II Immunoreactivity in Erythema Multiforme and its Variants: A Possible Aid in Histologic Diagnosis. 61
31599750 2020
13
IP-10/CXCR3 axis is associated with HHV-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms. 61
32037509 2020
14
Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017. 61
31997613 2020
15
Comment on: "Microbial Keratitis in Stevens-Johnson Syndrome: A Prospective Study". 61
31658166 2020
16
Common and critical inflammatory dermatoses every pathologist should know. 61
31676787 2020
17
Validation of a clinical assessment tool for cicatrising conjunctivitis. 61
31693934 2020
18
Fixed Drug Eruptions: An Update, Emphasizing the Potentially Lethal Generalized Bullous Fixed Drug Eruption. 61
32002848 2020
19
Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies. 61
31931437 2020
20
Genetic contribution of ABCC2 to Dubin-Johnson syndrome and inherited cholestatic disorders. 61
31544333 2020
21
RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31954192 2020
22
Attenuation of Wnt/β-catenin signaling in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31929762 2020
23
Is there an association between Stevens-Johnson Syndrome and vaccination? A systematic review. 61
31713580 2020
24
Treatment for oral lesions in pediatric patients with Stevens-Johnson's syndrome: A case report and literature review. 61
31923328 2020
25
Genetic Variants Associated with T-Cell Mediated Cutaneous Adverse Drug Reactions: A Prisma-Compliant Systematic Review - an EAACI Position Paper. 61
31899808 2020
26
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication. 61
31912576 2020
27
Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017. 61
31323695 2020
28
Preparation of placental tissue transplants and their application in skin wound healing and chosen skin bullous diseases - Stevens-Johnson syndrome and toxic epidermal necrolysis treatment. 61
31943788 2020
29
Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. 61
31896765 2020
30
Controlling oral hemorrhages in Steven-Johnson syndrome/toxic epidermal necrolysis. 61
31279017 2020
31
Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting. 61
31608511 2020
32
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. 61
31951804 2020
33
Long-Term Effect of a Treatment Protocol for Acute Ocular Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
31326519 2019
34
Laparoscopic cholecystectomy for cholecystolithiasis with Dubin-Johnson syndrome. 61
31832555 2019
35
Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. 61
30782092 2019
36
Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. 61
31898979 2019
37
Mutant GNLY is linked to Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
31642954 2019
38
Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review. 61
31897340 2019
39
[Cutaneous lichen planus following Stevens-Johnson syndrome: Wolf's isotopic response]. 61
31627928 2019
40
Stevens-Johnson syndrome/toxic epidermal necrolysis: a chronic condition? 61
31853947 2019
41
Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. 61
31912590 2019
42
Bronchiolitis obliterans as a long-term sequela of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. 61
30908698 2019
43
The psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients' lives: a Critically Appraised Topic. 61
31792924 2019
44
Depletion of regulatory FoxP3+ T cells in the pathogenesis of Stevens-Johnson syndrome induced by mogamulizumab. 61
31334834 2019
45
Evaluating Dry Eye and Meibomian Gland Dysfunction With Meibography in Patients With Stevens-Johnson Syndrome. 61
31205158 2019
46
Comment on 'Bronchiolitis obliterans as a long-term sequela of Stevens-Johnson syndrome and toxic epidermal necrolysis in children'. 61
31323139 2019
47
Timing of mucocutaneous symptoms and medication discontinuation in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. 61
31085266 2019
48
Contrast media and cutaneous reactions. Part 2: Delayed hypersensitivity reactions to iodinated contrast media. 61
31162717 2019
49
Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy. 61
31848905 2019
50
Glaucoma Management in Patients With Aniridia and Boston Type 1 Keratoprosthesis. 61
31247168 2019

Variations for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Expression for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Search GEO for disease gene expression data for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome.

Pathways for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

GO Terms for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Sources for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....